Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth.

Area of Science:

• Neonatal neurology
• Maternal-fetal medicine
• Pediatric neurodevelopment

Background:

• Chorioamnionitis is a significant risk factor for adverse neurodevelopmental outcomes in preterm infants.
• Antenatal magnesium sulfate (MgSO4) administration is explored as a neuroprotective strategy.
• Previous studies suggest potential benefits, necessitating further investigation in specific high-risk populations.

Purpose of the Study:

• To evaluate the neuroprotective efficacy of antenatal magnesium sulfate (MgSO4) in preterm neonates exposed to chorioamnionitis.
• To assess the impact of MgSO4 on a composite of stillbirth, mortality, and cerebral palsy (CP).
• To examine secondary outcomes including neonatal complications and neurodevelopmental delay.

Main Methods:

• Secondary analysis of a multicenter randomized controlled trial involving singleton pregnancies with chorioamnionitis delivering at ≥24 weeks gestation.
• Infants were categorized based on antenatal exposure to MgSO4 or placebo.
• Intention-to-treat analysis was employed, with univariate and multivariate statistical methods.

Main Results:

• The primary composite outcome occurred in 14.1% of the MgSO4 group versus 12.7% of the placebo group (RR 1.29).
• No significant differences were observed in the rates of stillbirth, death, moderate-to-severe CP, or neurodevelopmental delay between the groups.
• Subgroup analysis of infants born before 28 weeks gestation also showed no significant differences in primary or secondary outcomes.

Conclusions:

• Antenatal magnesium sulfate administration is not associated with improved neurodevelopmental outcomes in preterm infants exposed to chorioamnionitis.
• Current evidence from this study does not support a change in clinical guidelines regarding MgSO4 for neuroprotection in this context.
• Further research may be needed to identify specific subgroups or alternative interventions for neuroprotection.